---
document_datetime: 2023-09-21 21:42:29
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/fulvestrant-mylan-epar-all-authorised-presentations_en.pdf
document_name: fulvestrant-mylan-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.9484193
conversion_datetime: 2025-12-22 16:50:00.123593
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form    | Route of Administration   | Immediate Packaging        | Content (concentration)   | Pack size                                |
|------------------|-------------------|------------|------------------------|---------------------------|----------------------------|---------------------------|------------------------------------------|
| EU/1/17/1253/001 | Fulvestrant Mylan | 250 mg     | Solution for injection | Intramuscular use         | pre-filled syringe (glass) | 5 ml (50 mg/ml)           | 1 pre-filled syringe + 1 safety needle   |
| EU/1/17/1253/002 | Fulvestrant Mylan | 250 mg     | Solution for injection | Intramuscular use         | pre-filled syringe (glass) | 5 ml (50 mg/ml)           | 2 pre-filled syringes + 2 safety needles |
| EU/1/17/1253/003 | Fulvestrant Mylan | 250 mg     | Solution for injection | Intramuscular use         | pre-filled syringe (glass) | 5 ml (50 mg/ml)           | 4 pre-filled syringes + 4 safety needles |
| EU/1/17/1253/004 | Fulvestrant Mylan | 250 mg     | Solution for injection | Intramuscular use         | pre-filled syringe (glass) | 5 ml (50 mg/ml)           | 6 pre-filled syringes + 6 safety needles |